Table 3.
Group | n | Baseline titers (U/ml) | Anti-tetanus antibody titers at 14 days post-vaccination (U/ml) | Anti-tetanus antibody titers at 28 days post-vaccination (U/ml) |
Group A (vaccines alone on day 1) | 20 | 1.6 (106) | 11.4 (88) | 9.3 (104) |
Group B (vaccines 2 weeks before abatacept) | 20 | 1.9 (76) | 10.2 (71) | 8.7 (68)a |
Group C (vaccines 2 weeks after abatacept) | 19b | 2.3 (76) | 5.9 (112) | 5.6 (98) |
Group D (vaccines 8 weeks after abatacept) | 19c | 2.3 (54) | 9.0 (79) | 7.8 (85) |
an = 19 as one subject discontinued due to an adverse event (this discontinued patient only had samples collected at baseline and day 14). bSubject discontinued prior to vaccine administration on day 14 due to toxicology. cSubject discontinued prior to vaccine administration on day 56 due to toxicology.